World's Best Scientists 2026 revealed!
Christopher H. van Dyck

Christopher H. van Dyck

D-Index & Metrics

Neuroscience

D-Index
83
Citations
37209
World Ranking
1418
National Ranking
712

Medicine

D-Index
83
Citations
37238
World Ranking
15388
National Ranking
7762

Overview

Christopher H. van Dyck is affiliated with Yale University in the United States. Their academic work focuses extensively on neuroscience and medicine, with a particular emphasis on Alzheimer's disease and related neurodegenerative conditions.

Their research primarily covers these main fields of study:

  • Medicine
  • Neuroscience

Within these fields, van Dyck's subfields of study include:

  • Physiology
  • Psychiatry and Mental health
  • Cognitive Neuroscience
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Key research topics addressed in their work are:

  • Alzheimer's disease research and treatments
  • Dementia and Cognitive Impairment Research
  • Functional Brain Connectivity Studies
  • Neuroscience and Neuropharmacology Research
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Memory and Neural Mechanisms
  • Cholinesterase and Neurodegenerative Diseases

Van Dyck has contributed to several influential papers, including the following recent publications:

  • Lecanemab in Early Alzheimer's Disease, 2022, New England Journal of Medicine
  • Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease, 2022, The Journal of Prevention of Alzheimer s Disease
  • A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, 2021, Nature Medicine
  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease, 2020, Alzheimer s Research & Therapy
  • Trial of Solanezumab in Preclinical Alzheimer's Disease, 2023, New England Journal of Medicine

Their frequent co-authors include:

  • Adam P. Mecca
  • Ryan S. O'Dell
  • Richard E. Carson
  • Nabeel Nabulsi
  • Amy F.T. Arnsten

Van Dyck's research is regularly published in journals with a focus on Alzheimer's and related fields. Frequent publication venues are:

  • Alzheimer s & Dementia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • American Journal of Geriatric Psychiatry
  • Alzheimer s Research & Therapy
  • The Journal of Prevention of Alzheimer s Disease

Best Publications

  • Lecanemab in Early Alzheimer's Disease.

    Unknown

  • Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

    Ronald C. Petersen;Ronald G. Thomas;Michael Grundman;David Bennett

  • Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

    Unknown

  • Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

    Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas

  • Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

    Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez

  • Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

    Joseph F. Quinn;Rema Raman;Ronald G. Thomas;Karin Yurko-Mauro

  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

    S. Salloway;R. Sperling;S. Gilman;N.C.I. Fox

  • A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

    R. Scott Turner;Ronald G. Thomas;Suzanne Craft;Christopher H. van Dyck

  • Four distinct trajectories of tau deposition identified in Alzheimer’s disease

    Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  • High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Controlled Trial

    Paul S. Aisen;Lon S. Schneider;Mary Sano;Ramon Diaz-Arrastia

  • Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

    Christopher H. van Dyck

  • Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography

    Robert T Malison;Lawrence H Price;Robert Berman;Christopher H van Dyck

  • Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

    Michael F. Egan;James Kost;Tiffini Voss;Yuki Mukai

  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    Jacob W. Vogel;Yasser Iturria-Medina;Olof T. Strandberg;Ruben Smith

  • Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

    Vladimir Coric;Christopher H. van Dyck;Stephen Salloway;Niels Andreasen

  • Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.

    Ming-Kai Chen;Adam P. Mecca;Mika Naganawa;Sjoerd J. Finnema

  • Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

    Unknown

  • Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.

    Adam C. Kaufman;Santiago V. Salazar;Laura T. Haas;Jinhee Yang

  • Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

    Martin Farlow;Steven E. Arnold;Christopher H. van Dyck;Paul S. Aisen

  • Age-Related Decline in Dopamine Transporters: Analysis of Striatal Subregions, Nonlinear Effects, and Hemispheric Asymmetries

    Christopher H. van Dyck;John P. Seibyl;Robert T. Malison;Marc Laruelle

  • A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

    Stephen Salloway;Martin Farlow;Eric McDade;David B. Clifford

  • Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment

    Adam Fleisher;Michael Grundman;Clifford R. Jack;Ronald C. Petersen

  • Age-Related Decline in Striatal Dopamine Transporter Binding with Iodine-123-β-CITSPECT

    Christopher H. van Dyck;John P. Seibyl;Robert T. Malison;Marc Laruelle

  • High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease

    Paul S. Aisen;Lon S. Schneider;Mary Sano;Ramon Diaz-Arrastia

Frequent Co-Authors

Richard E. Carson
Richard E. Carson Yale University
Amy F.T. Arnsten
Amy F.T. Arnsten Yale University
Nabeel Nabulsi
Nabeel Nabulsi Yale University
Mika Naganawa
Mika Naganawa Yale University
John Seibyl
John Seibyl Yale University
Yiyun Huang
Yiyun Huang Yale University
Paul S. Aisen
Paul S. Aisen University of Southern California
Stephen Salloway
Stephen Salloway Brown University
Robert B. Innis
Robert B. Innis National Institutes of Health
Clifford R. Jack
Clifford R. Jack Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying neuroscience in the USA opens the door to a variety of interdisciplinary career paths. Many students interested in understanding the human brain and behavior also consider related degrees in psychology, counseling, and social work. For those seeking flexibility and affordability, pursuing an online degree in psychology can be a practical step toward roles in mental health, research, or education.

If you're interested in family dynamics or therapy, exploring mft masters programs can prepare you for a rewarding career as a marriage and family therapist. Another route is social work, and those wanting to quickly enter the field may want to know about the easiest msw online program options.

Affordability is often a key concern when choosing a graduate path. Understanding how much does a masters in psychology cost can help you make informed decisions about your education and future career. With these related online degrees, you can tailor your studies to your passion for neuroscience while expanding your professional opportunities.

Best Scientists Citing Christopher H. van Dyck

Trending Scientists